Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
197 studies found for:    Kaiser Permanente | Open Studies
Show Display Options
Rank Status Study
21 Not yet recruiting The Watch the Spot Trial
Conditions: Solitary Pulmonary Nodule;   Coin Lesion, Pulmonary;   Lung Neoplasms;   Carcinoma, Non-small-cell Lung
Interventions: Other: More Frequent Surveillance Strategy;   Other: Less Frequent Surveillance Strategy
22 Not yet recruiting Implementing Systematic Distress Screening in Breast Cancer
Condition: Breast Cancer
Intervention: Behavioral: Distress screening
23 Not yet recruiting Reducing Delay of Vaccination in Children Study
Condition: Communicable Diseases
Interventions: Behavioral: Tailored;   Behavioral: Untailored
24 Not yet recruiting Mom for Moms Study: Peer Delivery of Behavioral Activation for Depression During Pregnancy
Conditions: Depression;   Pregnancy
Interventions: Behavioral: Peer-BA for Pregnant Women;   Behavioral: Care as Usual
25 Recruiting The CREATE Wellness Study
Conditions: Diabetes;   Heart Disease;   Hypertension;   Dyslipidemia
Interventions: Behavioral: CREATE Wellness;   Other: Usual Care Control
26 Recruiting Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Condition: Colorectal Cancer
Intervention: Other: Auto Plus
27 Recruiting Palliative Care Intervention in Improving Symptom Control and Quality of Life in Patients With Stage II-IV Non-small Cell Lung Cancer and Their Family Caregivers
Conditions: Caregiver;   Psychological Impact of Cancer and Its Treatment;   Recurrent Non-small Cell Lung Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIB Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Other: Palliative Therapy;   Other: quality-of-life assessment;   Other: questionnaire administration
28 Recruiting An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding
Condition: Hemorrhage
Interventions: Biological: Kcentra®;   Biological: Plasma
Condition: Carotid Artery Disease
30 Unknown  Confirmation Trial of the Acorn CorCap Cardiac Support Device (CSD) at the Same Time as Mitral Valve Repair
Condition: Heart Failure
Intervention: Device: CorCap CSD
31 Recruiting Multicenter Prospective Cohort Study on Current Treatments of Legg-Calvé-Perthes Disease
Condition: Legg Calve Perthes Disease
Interventions: Procedure: osteotomy;   Procedure: multiple epiphyseal drilling
32 Recruiting Study of Two Surgical Drilling Techniques to Treat Juvenile Osteochondritis Dissecans of the Knee
Condition: Juvenile Osteochondritis Dissecans
Interventions: Procedure: Retro-articular drilling;   Procedure: Trans-articular drilling
33 Recruiting Decision Aids for the Management of Suspicious Occlusal Caries Lesions
Condition: Dental Caries
Interventions: Device: Spectra Device;   Device: DIAGNOdent
34 Recruiting Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Conditions: Recurrent Melanoma of the Skin;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Biological: Sargramostim
35 Recruiting Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Conditions: Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
36 Recruiting Lung-MAP: Palbociclib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
Conditions: Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Palbociclib
37 Recruiting Lung-MAP: Taselisib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
Conditions: Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Taselisib
38 Recruiting S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Conditions: Pancreatic Adenocarcinoma;   Resectable Pancreatic Carcinoma
Interventions: Drug: Fluorouracil;   Drug: Gemcitabine Hydrochloride;   Drug: Irinotecan Hydrochloride;   Drug: Oxaliplatin;   Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation;   Procedure: Pancreatectomy
39 Recruiting Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
Conditions: Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
40 Recruiting NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
Conditions: Advanced Malignant Neoplasm;   Lymphoma;   Refractory Malignant Neoplasm;   Solid Neoplasm
Interventions: Drug: Afatinib;   Drug: Akt inhibitor AZD5363;   Drug: Binimetinib;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dasatinib;   Drug: Defactinib;   Drug: FGFR Inhibitor AZD4547;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab Emtansine;   Drug: Vismodegib

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years